New drug trial targets Tough-to-Treat melanoma after immunotherapy fails
NCT ID NCT07237100
First seen Nov 19, 2025 · Last updated Apr 09, 2026 · Updated 16 times
Summary
This study is testing an experimental drug called mirdametinib in people with advanced melanoma that has a specific genetic change (an NF1 mutation) and has continued to grow despite previous immunotherapy. The main goals are to see if the drug is safe and if it can slow or stop the cancer's growth. This is a small, early-stage study enrolling 10 participants to gather initial data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
California Pacific Medical Center - Sutter Health
RECRUITINGSan Francisco, California, 94115, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.